Ulm

• Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis Ended
  2023-506046-24-00 4 2023-07-03 Ulcerative Colitis (UC)
• ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Ended
  2022-500536-11-01 5 2023-06-08 Moderately to severely active ulcerative colitis
• A Phase 2 Proof of Concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of OMS90 … Ended
  2022-501190-39-01 3 2023-05-15 Paroxysmal nocturnal hemoglobinuria
• A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended
  2022-501259-10-00 4 2023-04-14 Relapsed/Refractory Waldenstrom Macroglobulinemia (WM)
• A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended
  2022-501260-18-00 4 2023-04-14 Relapsed/refractory Richter Transformation (RT)
• A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancie … Ended
  2022-501261-46-00 4 2023-04-14 Relapsed/Refractory Burkitt Lymphoma (BL)
• A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended
  2022-501262-21-00 4 2023-04-14 Relapsed/Refractory Hairy Cell Leukemia
• A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease Ended
  2023-506872-29-00 4 2023-04-13 Alzheimer's Disease
• A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn’s Disease Ended
  2024-511089-36-00 4 2023-03-17 Crohn’s disease
• C4951012 - BHV3000-407: A Phase 4, Randomized, Double-blind, Placebo controlled Study to Evaluate the Efficacy and Tolerability of Rimegepan … Ended
  2024-513270-21-00 6 2023-03-14 migraine headaches with or without aura
• A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous … Ended
  2024-516300-41-00 5 2023-03-07 Multiple Myeloma
• Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma af … Ended
  2024-510590-14-00 5 2023-03-03 multiple myeloma
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effe … Ended
  2023-510317-26-00 4 2023-02-07 Amyotrophic Lateral Sclerosis
• A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran … Ended
  2023-503793-20-00 5 2023-01-18 Prevention of ischemic stroke in patients post acute non-cardioembolic
• A study to test whether BI 907828 helps people with cancer in the biliary tract, pancreas, lung, or bladder Ended
  2023-506369-79-00 4 2022-11-30 Pancreatic ductal adenocarcinoma
• A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of BIIB122 in participants … Ended
  2023-505645-12-00 4 2022-11-28 Parkinson's Disease
• Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia Ended
  2023-507748-35-00 1 2022-11-08 Acute Myeloid Leukemia
• A Phase 3 study to determine the Efficacy and Safety of Losmapimod in Treating Patients with Facioscapulohumeral Muscular Dystrophy (REACH) Ended
  2024-512737-33-00 5 2022-09-30 Facioscapulohumeral Muscular Dystrophy (FSHD)
• A Phase 3 Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease (Complication … Ended
  2024-516064-28-00 5 2022-09-27 Acute Graft Versus Host Disease
• Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102) Ended
  2023-505458-16-00 5 2022-09-13 Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpressio
• Early Reperfusion Therapy for Recovery of Vision in Acute Central Retinal Artery Occlusion Ended
  2023-507388-21-00 5 2022-09-08 Acute non-arteritic central retinal artery occlusion (CRAO)
• A multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the rate of weekly lipoprotein apheresis ses … Ended
  2023-508324-35-00 5 2022-08-19 Apheresis
• A Phase 2a, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects With Huntington’s D … Ended
  2023-509835-26-00 4 2022-07-06 Huntington’s Disease
• Phase II Study of Fedratinib and Nivolumab Combination in Patients with Myelofibrosis and Resistance or Suboptimal Response to JAK-inhibitor … Ended
  2024-513953-64-00 4 2022-06-23 Primary and secondary Myelofibrosis

Showing 505–528 of 569 trials